Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partner...
03 Février 2021 - 2:55PM
Telo Genomics Corp. (TSX-V: TELO) (the
“Company” or
“TELO”) is pleased
to announce that the Company has entered into a consulting
agreement with the biomedical industry veteran Gregg Mayer, Founder
& Principal of BioCore Strategies, LLC, Boston, Massachusetts,
USA, and former executive of Abbott Diagnostics, Siemens and a
number of early-stage biopharma and medical device companies, both
public and privately held. Mr. Mayer will lead TELO’s efforts to
develop and execute the Company’s industry partnership strategy
with Biopharma and Diagnostics industries.
“I have previously collaborated with Gregg and
am thrilled to have him onboard leading Telo Genomics efforts to
develop the Company’s industry partnership strategy,” said Guido
Baechler, TELO Chairman. “Gregg brings 35 years of executive
experience in the biomedical industry, particularly in crafting
diagnostics-pharma partnerships”.
Mr. Mayer founded BioCore Strategies, LLC in
2010, a Massachusetts-based consultancy to help small/mid-size
companies develop and commercialize innovative medical
technologies. Since 1984 Mr. Mayer held key executive and expert
consulting roles with several pharmaceutical and medical device
companies. In these roles, Mr. Mayer focused on the design,
development, and commercialization of innovative diagnostics
technologies, and has led numerous collaborations with biopharma
industry. He was elected Chairman of the Medical Imaging Contrast
Agent Association (MICAA), a Washington DC-based lobby group
focused on regulatory and reimbursement policy. Gregg earned a
Bachelor of Business Administration degree from the University of
Texas at Austin, and an MBA from Northwestern University’s Kellogg
School of Management.
“I am excited to work with the Telo Genomics
team” said Gregg Mayer. “The TeloView® technology is unique and
innovative, with the added advantage of delivering single-cell
analytics to a liquid biopsy platform. These leading-edge
characteristics will help in establishing new partnerships with
biopharma & diagnostics companies driving precision medicine to
identify patients who will benefit from a specific treatment,
predict patient response to treatment, and monitor treatment
outcomes over time.”
In connection with the consulting agreement
issued between TELO and Gregg Mayer, the Company has granted Mr.
Mayer 120,000 of Company’s stock options vesting over 6 months at
an exercise price of $0.49 per stock option in accordance to TELO’s
approved stock options plan and subject to final TSXV approval.
About Telo Genomics
Telo Genomics is a biotech company pioneering
the most comprehensive telomere platform in the industry with
powerful applications and prognostic solutions. These include
liquid biopsies and related technologies in oncology and
neurological diseases. Liquid biopsy is a rapidly growing field of
significant interest to the medical community for being less
invasive and more easily replicated than traditional diagnostic
approaches. By combining our team’s considerable expertise in
quantitative analysis of 3D telomeres with molecular biology and
artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate
products that improve day-to-day care for patients by serving the
needs of pathologists, clinicians, academic researchers and drug
developers. The benefits of our proprietary technology have been
substantiated in over 150 peer reviewed publications and in 25
clinical studies involving more than 3,000 patients with multiple
cancers and Alzheimer’s disease. Our lead application, Telo-MM is
being developed to provide important, actionable information to
medical professionals in the treatment of Multiple Myeloma, a
deadly form of blood cancer. For more information please visit
www.telodx.com.
For further information, please
contact:
Hugh Rogers,
Director416-673-8487info@telodx.comMaRS Centre, South Tower, 101
College Street, Suite 200, Toronto, ON, M5G 1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“intends”, “will”, or variations of such words and phrases or
statements that certain actions, events or results “will” occur.
Forward-looking statements regarding the clinical efficacy of
products, commercial viability of products, use of proceeds, and
the ability of the TeloViewTM platform to deliver personalized
medicine resulting in better treatments and outcomes are based on
the Company’s estimates and are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information,
including capital expenditures and other costs. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. The Company will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024